Avidity Partners Management LP Esperion Therapeutics, Inc. Transaction History

Avidity Partners Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$11.34 - $21.37 $4.54 Million - $8.55 Million	-400,000 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$19.4 - $28.71 $7.76 Million - $11.5 Million	400,000 New	400,000 $8.46 Million
Q3 2020 Nov 16, 2020	SELL	$31.18 - $52.71 $17.5 Million - $29.5 Million	-559,700 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$30.04 - $51.31 $10.7 Million - $18.2 Million	354,700 Added 173.02%	559,700 $28.7 Million
Q1 2020 Jun 17, 2020	BUY	$27.44 - $73.84 $5.63 Million - $15.1 Million	205,000 New	205,000 $6.46 Million
Q1 2020 May 15, 2020	SELL	$27.44 - $73.84 $3.58 Million - $9.63 Million	-130,400 Closed	0 $0
Q4 2019 Jun 17, 2020	BUY	$35.4 - $59.82 $4.62 Million - $7.8 Million	130,400 New	130,400 $7.78 Million

213

128M

1.78M

1.27M

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $99.8M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.